miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23
New Award – miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23. Prof Leedman and the team were successful in being awarded a Development Grant for two years to help drive the further development of mRx-7 into a therapy for liver cancer.
mRx-7 presented at the American Association for Cancer Research
At a virtual conference hosted by the American Association for Cancer Research (AACR), April 10-15 2021, preliminary results of mRx-7 were presented by Prof Peter Leedman. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and […]
mRx-7 and microRNAs in cancer presented to the National Gene Therapy meeting in Brisbane
National Gene Therapy Meeting Recent findings for the progression of mRx-7 were presented at the Annual Joint Scientific Meeting hosted by the Australian Society for Stem Cell Research (ASSCR), Australasian Gene and Cell Therapy Society (AGCTS), and the International Society for Cell & Gene Therapy (ISCT) in Brisbane, Queensland, Australia. This conference, which spanned November […]
mRx-7 and microRNAs in cancer presented to Sun Yat-Sen University Hospital, China
In July of 2019, Prof Peter Leedman visited Sun Yat-Sen University Hospital, Guangzhou, Guangdong, China to present the latest findings for the progression of mRx-7 as a new anti-cancer therapeutic.